Clinical trial · Observational
Oral Complications in Hematological Malignancies
Prevalence and Types of Oral Complications Occuring in Hematological Malignancy Patients.:Cross Sectional Study
NCT05758207CI-TRIAL-00068803unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to evaluate the prevalence and types of oral complications found in patients diagnosed with haematological malignancy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Calculate the prevalence of oral complications.
- timeFrame
- Baseline
- description
- Calculate the prevalence of oral complications with special attention to infectious complications in hematological malignancy patients.
Secondary outcomes (1)
- measure
- the morbidity related to oral complication in haematological malignancy patients.
- timeFrame
- Baseline
- description
- Study the morbidity related to oral complication in haematological malignancy patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * All newly diagnosed patients elder than 18 years with hematological malignancy start from January 1st 2022 to January 1st 2023 including Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Chronic lymphoblastic leukemia Non-Hodgkin lymphoma Hodgkin lymphoma Multiple myeloma Exclusion Criteria: * Patient younger than 18 years old Patients previously diagnosed Patients refused to participate in our study
References
Publications (2)
- BACKGROUNDEmodi O, Ohayon C, Bilder A, Capucha T, Wolff A, Rachmiel A. Postextraction Mucormycosis in Immunocompromised-Patient Management and Review of Literature. J Oral Maxillofac Surg. 2021 Jul;79(7):1482-1491. doi: 10.1016/j.joms.2021.01.019. Epub 2021 Jan 25. PMID 33617788
- BACKGROUNDElad S, Zadik Y, Yarom N. Oral Complications of Nonsurgical Cancer Therapies. Atlas Oral Maxillofac Surg Clin North Am. 2017 Sep;25(2):133-147. doi: 10.1016/j.cxom.2017.04.006. No abstract available. PMID 28778303